S. 9%.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements.
Benzinga’s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. S.
equity market opening. Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the Analyst Stock Ratings page.
One of the ways traders can sort through Benzinga’s extensive database of analyst ratings is by analyst accuracy. Analyst: Timothy Arcuri Analyst Firm: UBS Ratings Accuracy: 86% Latest Rating: Maintained a Buy rating on Allegro MicroSystems Inc (NASDAQ:ALGM) and cut the price target from $50 to $48 on Oct.
30. This analyst sees around 56% upside in the stock.
Recent News: On Oct. 29, Allegro MicroSystems posted upbeat earnings for the second quarter.
Analyst: Harlan Sur Analyst Firm: JP Morgan Ratings Accuracy: 83% Latest Rating: Maintained a Neutral rating on Intel Corp (NASDAQ:INTC) and cut the price target from $85 to $80 on Oct. 30.
This analyst sees around 23% upside in the stock. Recent News: On Oct.
29, the company issued weak fourth-quarter forecast. Analyst: Doug Anmuth Analyst Firm: JP Morgan Ratings Accuracy: 82% Latest Rating: Maintained a Neutral rating on Reddit Inc (NYSE:RDDT) and cut the price target from $185 to $150 on Oct.
30. This analyst sees around 63% gain in the stock.
Recent News: On Oct. 29, Reddit, reported third-quarter results that topped expectations, but issued weaker-than-expected guidance.
Analyst: Myles Walton Analyst Firm: UBS Ratings Accuracy: 82% Latest Rating: Maintained a Neutral rating on L3harris Technologies, Inc (NYSE:LHX) and raised the price target from $264 to $293 on Oct. 30.
This analyst expects around 6% gain in the stock. Recent News: On Oct.
29, L3Harris Technologies reported better-than-expected third-quarter financial results and raised its FY26 guidance. Analyst: Joon Lee Analyst Firm: UBS Ratings Accuracy: 81% Latest Rating: Maintained a Buy rating on Alnylam Pharmaceuticals, Inc.
(NASDAQ:ALNY) and cut the price target from $354 to $329 on Oct. 30.
This analyst sees around 98% jump in the stock. Recent News: On Oct.
29, Alnylam Pharmaceuticals posted strong quarterly sales.
